XOMA (NASDAQ:XOMA) is a biotech entity focused on the discovery and development of innovative antibody-based therapeutics. The company’s operations revolve around licensing its extensive portfolio of patents and clinical development products to other biotechnology and pharmaceutical companies. XOMA's projects often involve developing partnerships and collaborations to advance the research and development of drugs with the potential to address a wide range of diseases and conditions. The primary objective of XOMA is to leverage its proprietary technology and scientific expertise to create a robust pipeline of therapeutic candidates, which provides the foundation for future growth and innovation in the medical field.